Joseph Luke Watson

Joseph Luke Watson

Auto-generated profile, based on publicly available information

Joseph Luke Watson

Department of Biochemistry, University of Washington, Seattle, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2022 in Science
Verified
Journal Article
Open access
JWJue Wang
Jue Wang
SLSidney Lisanza
Sidney Lisanza
DJDavid Juergens
David Juergens
DTDoug Tischer
Doug Tischer
JWJoseph L. Watson
Joseph L. Watson
DBDavid Baker
David Baker
The binding and catalytic functions of proteins are generally mediated by a small number of functional residues held in place by the overall protein structure. Here, we describe deep learning approaches for scaffolding such functional sites without needing to prespecify the fold or secondary structure of the scaffold. The first approach, “constrained hallucination,” optimizes sequences such that their predicted structures contain the desired functional site. The second approach, “inpainting,” starts from the functional site and fills in additional sequence and structure to create a viable protein scaffold in a single forward pass through a specifically trained RoseTTAFold network. We use these two methods to design candidate immunogens, receptor traps, metalloproteins, enzymes, and protein-binding proteins and validate the designs using a combination of in silico and experimental tests.

18 December 2023 in Nature
Verified
Journal Article
Open access
PDF file
STSusana Vázquez Torres
Susana Vázquez Torres
PLPhilip J. Y. Leung
Philip J. Y. Leung
PVPreetham Venkatesh
Preetham Venkatesh
ILIsaac D. Lutz
Isaac D. Lutz
FHFabian Hink
Fabian Hink
DBDavid Baker
David Baker
Many peptide hormones form an α-helix on binding their receptors1–4, and sensitive methods for their detection could contribute to better clinical management of disease5. De novo protein design can now generate binders with high affinity and specificity to structured proteins6,7. However, the design of interactions between proteins and short peptides with helical propensity is an unmet challenge. Here we describe parametric generation and deep learning-based methods for designing proteins to address this challenge. We show that by extending RFdiffusion8 to enable binder design to flexible targets, and to refining input structure models by successive noising and denoising (partial diffusion), picomolar-affinity binders can be generated to helical peptide targets by either refining designs generated with other methods, or completely de novo starting from random noise distributions without any subsequent experimental optimization. The RFdiffusion designs enable the enrichment and subsequent detection of parathyroid hormone and glucagon by mass spectrometry, and the construction of bioluminescence-based protein biosensors. The ability to design binders to conformationally variable targets, and to optimize by partial diffusion both natural and designed proteins, should be broadly useful.

5 November 2025 in Nature
Verified
Journal Article
Open access
PDF file
NBNathaniel R. Bennett
Nathaniel R. Bennett
JWJoseph L. Watson
Joseph L. Watson
RRRobert J. Ragotte
Robert J. Ragotte
ABAndrew J. Borst
Andrew J. Borst
DSDéjenaé L. See
Déjenaé L. See
DBDavid Baker
David Baker
Despite the central role of antibodies in modern medicine, no method currently exists to design novel, epitope-specific antibodies entirely in silico. Instead, antibody discovery currently relies on immunization, random library screening or the isolation of antibodies directly from patients1. Here we demonstrate that combining computational protein design using a fine-tuned RFdiffusion2 network with yeast display screening enables the de novo generation of antibody variable heavy chains (VHHs), single-chain variable fragments (scFvs) and full antibodies that bind to user-specified epitopes with atomic-level precision. We experimentally characterize VHH binders to four disease-relevant epitopes. Cryo-electron microscopy confirms the binding pose of designed VHHs targeting influenza haemagglutinin and Clostridium difficile toxin B (TcdB). A high-resolution structure of the influenza-targeting VHH confirms atomic accuracy of the designed complementarity-determining regions (CDRs). Although initial computational designs exhibit modest affinity (tens to hundreds of nanomolar Kd), affinity maturation using OrthoRep3 enables production of single-digit nanomolar binders that maintain the intended epitope selectivity. We further demonstrate the de novo design of scFvs to TcdB and a PHOX2B peptide–MHC complex by combining designed heavy-chain and light-chain CDRs. Cryo-electron microscopy confirms the binding pose for two distinct TcdB scFvs, with high-resolution data for one design verifying the atomically accurate design of the conformations of all six CDR loops. Our approach establishes a framework for the computational design, screening and characterization of fully de novo antibodies with atomic-level precision in both structure and epitope targeting.

18 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NBNathaniel R. Bennett
Nathaniel R. Bennett
JWJoseph L. Watson
Joseph L. Watson
RRRobert J. Ragotte
Robert J. Ragotte
ABAndrew J. Borst
Andrew J. Borst
DSDéjenaé L. See
Déjenaé L. See
DBDavid Baker
David Baker
Despite the central role that antibodies play in modern medicine, there is currently no method to design novel antibodies that bind a specific epitope entirely in silico . Instead, antibody discovery currently relies on animal immunization or random library screening approaches. Here, we demonstrate that combining computational protein design using a fine-tuned RFdiffusion network alongside yeast display screening enables the generation of antibody variable heavy chains (VHHs) and single chain variable fragments (scFvs) that bind user-specified epitopes with atomic-level precision. To verify this, we experimentally characterized VHH binders to four disease-relevant epitopes using multiple orthogonal biophysical methods, including cryo-EM, which confirmed the proper Ig fold and binding pose of designed VHHs targeting influenza hemagglutinin and Clostridium difficile toxin B (TcdB). For the influenza-targeting VHH, high-resolution structural data further confirmed the accuracy of CDR loop conformations. While initial computational designs exhibit modest affinity, affinity maturation using OrthoRep enables production of single-digit nanomolar binders that maintain the intended epitope selectivity. We further demonstrate the de novo design of single-chain variable fragments (scFvs), creating binders to TcdB and a Phox2b peptide-MHC complex by combining designed heavy and light chain CDRs. Cryo-EM structural data confirmed the proper Ig fold and binding pose for two distinct TcdB scFvs, with high-resolution data for one design additionally verifying the atomically accurate conformations of all six CDR loops. Our approach establishes a framework for the rational computational design, screening, isolation, and characterization of fully de novo antibodies with atomic-level precision in both structure and epitope targeting.

6 January 2021 in Nature
Verified
Journal Article
Closed access
PDF file
ABAriel J. Ben-Sasson
Ariel J. Ben-Sasson
JWJoseph L. Watson
Joseph L. Watson
WSWilliam Sheffler
William Sheffler
MJMatthew Camp Johnson
Matthew Camp Johnson
ABAlice Bittleston
Alice Bittleston
DBDavid Baker
David Baker

10 December 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
JWJoseph L. Watson
Joseph L. Watson
DJDavid Juergens
David Juergens
NBNathaniel R. Bennett
Nathaniel R. Bennett
BTBrian L. Trippe
Brian L. Trippe
JYJason Yim
Jason Yim
DBDavid Baker
David Baker
There has been considerable recent progress in designing new proteins using deep learning methods 1–9 . Despite this progress, a general deep learning framework for protein design that enables solution of a wide range of design challenges, including de novo binder design and design of higher order symmetric architectures, has yet to be described. Diffusion models 10,11 have had considerable success in image and language generative modeling but limited success when applied to protein modeling, likely due to the complexity of protein backbone geometry and sequence-structure relationships. Here we show that by fine tuning the RoseTTAFold structure prediction network on protein structure denoising tasks, we obtain a generative model of protein backbones that achieves outstanding performance on unconditional and topology-constrained protein monomer design, protein binder design, symmetric oligomer design, enzyme active site scaffolding, and symmetric motif scaffolding for therapeutic and metal-binding protein design. We demonstrate the power and generality of the method, called RoseTTAFold Diffusion (RF diffusion ), by experimentally characterizing the structures and functions of hundreds of new designs. In a manner analogous to networks which produce images from user-specified inputs, RF diffusion enables the design of diverse, complex, functional proteins from simple molecular specifications.